

Research Article

Calcineurin: A Ca²⁺-Activated Protein Phosphatase Therapeutic Strategies and Involvement in ICV STZ Induced Alzheimer's type Dementia

Rimpi Arora^{1*}; Rahul Deshmukh¹; Om Prakash Agrawal²;
PL Sharma¹

¹Division of Neuropharmacology, Department of
Pharmacology, ISF College of Pharmacy, Punjab, India

²Bhabha Pharmacy Research Institute, Bhabha
University, Bhopal-462046, Madhya Pradesh, India

*Corresponding author: Rimpi Arora

Division of Neuropharmacology, Department of
Pharmacology, ISF College of Pharmacy, Ferozepur Road,
NH 95, Ghal Kalan, Moga-142001, Punjab, India.

Tel: 91-01851-245726; Fax: 91-01851-510019

Email: om11agra85@gmail.com

Received: April 15, 2024

Accepted: May 20, 2024

Published: May 27, 2024

Introduction

Prevalence of Dementia

Number of older people (taking the conventional definition as aged 65 or over), particularly the number of very old people (aged 80 and above) will increase substantially over the next fifty years in all countries, although rates of ageing vary greatly between countries. Currently 8% of western population is affected from dementia [1,2]. By 2025 this figure is expected to double with 71 per cent of these likely to live in developing countries, making the need for prevention of an incurable disease crucial. In U.K. 20% of the population is 65 and older, particularly in England, 16% of the population was aged 65 or over and 4% aged 80 or over in 2005. By 2050 it is expected that the number of people aged 65 or over will grow from 8 million to almost 15 million (by which time this number will represent 25% of the projected total population), while the number aged 80 or over will grow from 2 million to just over 6 million (equivalent to 10% of the total population) and 10-15% have mild, early and borderline demented states [3].

Types and Causes of Dementia

Dementia is caused by a disease that damages tissues in the brain causing disturbed brain functioning. Dementia is charac-

Abstract

Sporadic type of Alzheimer's Disease (SAD) is associated with various neurodegenerative and metabolic alterations. Among these, Insulin downstream Phospho-Inositol-3 Kinase (PI3K/Akt) signaling pathway showed drastic abnormalities of Akt/Protein Kinase B (PKB) level, activation of both glycogen synthase kinase 3 α and 3 β and deregulating phosphorylated/non-phosphorylated GSK-3 α and 3 β , imbalance between kinases and phosphatases particularly marked decrease in Protein Phosphatase-2A (PP2A), responsible for tau dephosphorylation and significant increase in Mitogen Activated Protein Kinase (MAPK), Extracellular Regulated Kinase (ERK) and c-JUN-N-Terminal Kinase (JNK) implicating in SAD pathogenesis. Moreover, Ca²⁺/calmodulin-dependent protein serine-threonine phosphatase 2B (PP2B) also known as Calcineurin attracted attention as a potential modulator of both learning and memory function and cell degeneration. Furthermore, PP2B is over expressed in AD and have been linked to A β deposition and Tau tangle formation. Favorable modulator of PP2B found to beneficial in a variety of experimental models of SAD. In this review, we provide an overview on PP2B and its implication in the pathogenesis of SAD.

Keywords: PP2B; MAPK; Alzheimer's disease; ICV-STZ; Memory; Oxidative Stress

terized by reversible and irreversible causes. There are several things which could result in reversible dementia and these dementias are treatable. These include dementia due to long-term substance abuse, tumors that can be removed, subdural hematoma, accumulation of blood beneath the outer covering of the brain that result of head injury, normal pressure hydrocephalus, hypothyroidism, toxic reactions like drug use and nutritional deficiencies like vitamin B12 and folate deficiencies [4]. Some of the irreversible and non-treatable cause of dementia includes diseases that cause degeneration or loss of nerve cells in the brain such as AD [5], PD [6], and HD [7], multi-infarct dementia (dementia due to multiple small strokes, also known as vascular dementia) [8], excessive alcohol use [9], infections that affect the brain and spinal cord, such as Acquired-Immune Deficiency Syndrome (AIDS) dementia complex [10] and Creutzfeldt-Jakob disease. Some people have a combined type of dementia involving both AD and vascular dementia [11].

Symptoms of Dementia

The most common symptoms that are mostly associated with dementia are delirium from a sudden medical problem,

psychosis, aggression, anger, insomnia or “sundowning” (confusion in late afternoon or early evening), anxiety, depression, personality and behavior changes, apathy and withdrawal, progressive and frequent memory loss [12,13].

Alzheimer’s Disease

Alzheimer’s disease is the most common dementia in the elderly population (> 65 years) associated with progressive neurodegeneration of the Central Nervous System (CNS) [14]. Clinically, AD typically begins with a subtle decline in memory and progresses to global deterioration in cognitive and adaptive functioning [15]. The majority of AD cases occur sporadically, what suggested that they could arise through interactions among various genetic and environmental factors. Current epidemiological investigations show that midlife hypertension, cardiovascular diseases, hypercholesterolemia, diabetes, obesity, inflammation, and viral infections can significantly contribute to the development and progression of AD, whereas active engagement in social, mental and physical activities may delay the onset of the disease [16].

Prevalence of AD

AD is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged 65 and older. Whereas other major causes of death have been on the decrease, deaths attributable to AD have been rising dramatically. Between 2000 and 2006, deaths attributable to AD increased 47%. An estimated 5.3 million Americans have AD; the approximately 200,000 persons under age 65 years with AD comprise the younger-onset AD population. The prevalence of AD increases with age from 4% in the 65 to 75 years age group to 19% in the 85 to 89 years age group, and the incidence of AD increases from 7/1000 in the 65 to 69 years age group to 118/1000 in the 85 to 89 years age group [17]. Every 70 seconds, someone in America develops AD; by 2050, this time is expected to decrease to every 33 seconds. Over the coming decades, the “baby-boom” population is projected to add 10 million people to these numbers. In 2050, the incidence of AD is expected to approach nearly a million people per year with a total estimated prevalence of 11 to 16 million people [18]. A minority of around 400 families worldwide can be grouped as familial in origin, whereas the majority of all Alzheimer cases (approx. 25 million worldwide) are sporadic in origin whose clinical manifestation appear in old age and ultimately affects almost half of the population over age 85 [19,20].

Symptoms and Stages of AD

AD can affect different people in different ways, but the most common symptom pattern begins with gradually worsening difficulty in remembering new information. This is because disruption of brain cells usually begins in regions involved in forming new memories [21]. In early stages of the disease, people may experience irritability, anxiety or depression. In later stages, other symptoms may occur including sleep disturbances, physical or verbal outbursts, emotional distress, restlessness, pacing, shredding paper or tissues and yelling, delusions (firmly held belief in things that are not real), and hallucinations (seeing, hearing or feeling things that are not there). As damage spreads, individuals also experience confusion, disorganized thinking, impaired judgment, trouble expressing themselves and disorientation to time, space and location, which may lead to unsafe wandering and socially inappropriate behavior. In advanced AD peoples need help with bathing, dressing, using the bathroom,

eating and other daily activities. Those in the final stages of the disease lose their ability to communicate, fail to recognize loved ones and become bed-bound and reliant on care [17].

Types of AD

AD is classified into two types based on etiology, onset of symptoms, pathophysiological, biochemical and genetic alterations into Familial (FAD) and Sporadic (SAD) cases [22].

Early onset Familial type AD

The first one is the very rare autosomal dominant early-onset familial type (FAD) is caused by missense mutations in the Amyloid Precursor Protein (APP) gene on chromosome 21, in the presenilin (PS)-1 gene on chromosome 14 and in the PS -2 gene on the chromosome 1 [23]. The genetic abnormalities on chromosomes 1, or 14, or 21 are all characterized by the permanent generation of Amyloid Beta (A β) 1–40 and in particular A β 1–42, beginning early in life [24]. Both these derivatives of APP reduce the binding of insulin to its receptor and receptor autophosphorylation [25]. The disruption of autophosphorylation by ATP may result in a decrease/lack of receptor tyrosine kinase activity and, thus, in a failure of post receptor effects exerted via insulin receptor substrate (IRS)-1 [26]. This dysfunction of the insulin signal transduction cascade may cause a drastic fall in the cerebral metabolism of glucose in FAD [27,28]. Regardless the primary cause and clinical form of AD, the amyloid cascade hypothesis proposes that both conditions lead to A β 1-42 accumulation, oligomerization and plaque formation, which further initiates a whole range of pathological cascade effects; microgliosis and astrocytosis [29], inflammatory response [17], oxidative [30], and nitrosative stress [31], Ca²⁺ dysregulation [32], mitochondrial dysfunction [26], neuronal/neuritic dysfunction, cell death [33], neurotransmitter deficits [34], and finally, memory loss [35]. In parallel, oxidative stress and neurotransmitter deficits induce kinase/phosphatase activity imbalance [36] which at the level of tau protein (microtubule-associated protein that stimulates the generation and stabilization of microtubules within cells, and control axonal transport of vesicles results in accumulation of hyperphosphorylated tau protein and formation of NFT which contribute to memory loss [37].

Late-onset Sporadic Type AD

In contrast to early onset FAD, aging is the main risk factor for late-onset SAD. Aging of the brain is associated with a multitude of inherent changes in cerebral glucose/energy metabolism, its control, and related pathways at cellular, molecular and genetic levels [38]. Numerous changes are accentuated by stress particularly functional imbalances of regulative systems, such as (1) energy production (reduced) and energy turnover (increased), (2) insulin action (reduced) and cortisol action (increased) due to a shift in the hypothalamic pituitary–adrenal axis to an increased basal tone [39], (3) acetylcholine action (reduced) and noradrenaline action (increased), indicating sympathetic tone, obviously also reducing insulin secretion after glucose stimulation and (4) shift in the gene expression profile from anabolic (reduced) to catabolic (increased) in distinct brain areas such as cortex, hippocampus and hypothalamus [40].

Neurochemical Changes in SAD

(A) Changes of the Brain Insulin Signaling Cascade

Research of the brain insulin system has been more pronounced in the last decade, particularly regarding its function

in the brain. There is a growing interest in finding the role of neuronal insulin signaling cascade in the brain, and off course in the brain of SAD. Recent data indicate that brain insulin deficiency and insulin resistance brain state are related to the late onset SAD [41]. In line with this decreased brain insulin protein and its mRNA levels were found post mortem in the brain (frontal cortex, hippocampus [42], while IR density was found to be increased and tyrosine kinase activity decreased [43]. Interestingly, strikingly reduced expression of genes encoding Insulin like Growth Factor-1 (IGF-1) and IGF-1 receptor has also been found in the frontal cortex, hippocampus and hypothalamus of patients with AD post mortem [42]. Regarding the downstream IR signaling pathways, reduced levels of PI3K have been found [44]. Regional specificity of changes and difference in AD severity stage probably account for some inconsistency in results reported in relation to Akt/PKB and GSK-3 α/β alterations, whose phosphorylated form were mainly found to be decreased [45,46]. In line with this, increased activity of GSK-3 found in hippocampus and hypothalamus could be related to decreased activity of Akt/PKB found in the same regions [43]. Recent data have pointed to another important enzyme, involved in tau dephosphorylation, the protein phosphatase 2A (PP2A), which can directly dephosphorylate tau [47]. It has been revealed a significant reduction in the total amount of PP2A in frontal and temporal cortices of SAD patients. Thus, it seems likely that hyperphosphorylated tau formation is the consequence of increased GSK-3 β [48,49].

(B) Reduced Glucose and Energy

Early and severe abnormalities were found in cerebral glucose metabolism which worsened in parallel with the dementia symptoms [50,35]. It includes the diminished activity of the pyruvate dehydrogenase complex yielding reduced levels of acetyl-CoA [51]. As a consequence, the reduced glycolytic glucose breakdown, the formation of fructose-6-phosphate may be diminished so that the availability of uridine-diphospho-N-acetylglucosamine (UDP-GlcAc) necessary for protein-OGlcNAcylation is decreased [52]. Another pathophysiologic consequence of the markedly perturbed glucose metabolism is the fall of ATP production from glucose by around 50% in the beginning of SAD, declining thereafter throughout the course of the disease [8].

(C) Reduced ATP Availability

A decisive pathophysiological consequence of the markedly perturbed glucose metabolism is a decrease in ATP production from glucose by around 50% in the beginning of SAD. The oxidative utilization of substrates other than glucose restores ATP formation to 80% of normal, but thereafter ATP levels decrease throughout the course of the disease [53]. This energy deficit may compromise ATP-dependent processes in a hierarchical manner including cellular and molecular mechanisms in particular in the endoplasmic reticulum and Golgi apparatus [54]. A depletion of cellular ATP prevents the dissociation of chaperone/protein complexes and thus blocks secretion of these proteins [55]. Additionally, ATP depletion results in the degradation of membrane phospholipids [56].

(D) Acetylcholine Neurotransmission Changes

Oxidative energy metabolism is important for the undisturbed function and structure of the brain. Both the neurotransmitter Acetylcholine (ACh) and the membrane sterol constituent cholesterol are derived from the glucose metabo-

lite, acetyl-CoA [57]. As a result of the deficits in glucose and energy metabolism and due to the reduced activity of Choline Acetyltransferase (ChAT), the synthesis of ACh in the presynaptic neuron is markedly diminished [58].

Neuropathological Hallmarks of AD

Two main neuropathological hallmarks are found in the brain of patients with familial and sporadic AD are (1) NFT and (2) amyloid plaques [48,59].

Tau Protein

NFT consist of intracellular protein deposits made of hyperphosphorylated tau protein [60]. Tau protein is a microtubule-associated protein which is involved in stabilization and promotion of microtubules but when hyperphosphorylated it gains a toxic function which is lethal for the neurons [61]. There is a growing body of evidence that changes in insulin and Insulin Receptor (IR) signaling cascade in the brain of people with AD and have an influence on the metabolism of APP and A β accumulation and in maintaining of balance between phosphorylated and nonphosphorylated tau protein [48,62].

Amyloid Beta

Extracellular amyloid plaques predominantly consist of aggregates of neurotoxic A β 1-42 generated in vivo by specific, proteolytic cleavage of APP [63,23]. Classical and also leading amyloid cascade hypothesis assumes that pathological assemblies of A β are the primary cause of both AD forms and all other neuropathological changes (cell loss, inflammatory response, oxidative stress, neurotransmitter deficits and at the end loss of Cognitive function are downstream consequences of A β accumulation [64].

Intracerebroventricular Streptozotocin Induced Neurotoxicity: An Animal Model of SAD

Considering the presence of insulin (from both periphery and brain) and IRs in the brain, an experimental rat model was developed by using Streptozotocin (STZ) administered Intracerebroventricularly (ICV) in doses of up to 100 times lower (per kg body weight) than those used peripherally to induce an insulin resistant brain state [65,51]. ICV-STZ rodent model is produced by a single or multiple (up to 3 times within one month) injections of a cytotoxic drug STZ, bilaterally into the lateral cerebral ventricle of an adult rat, first reported in 1990 [66]. Although learning and memory are impaired within 4 weeks in all experimental models of AD [67], however, no single model was determined to be truly representative of SAD characterized by abnormalities in neuronal IRs signaling. ICV-STZ reproduces a number of important aspects of SAD-type neurodegeneration within 1 month of ICV-STZ injection (s) and therefore provides supportive evidence that SAD may be caused in part by neuronal insulin resistance, i.e. brain diabetes [68].

STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose) is a drug selectively toxic for insulin producing/secreting cells both in the periphery as well as in the brain [69] and consequently ICV-STZ impairs the insulin-IR system [70]. Reflection on some of the earlier findings in AD, including the impaired glucose utilization, mitochondrial dysfunction, reduced ATP production, and energy dysregulation prompted consideration of the hypothesis that these abnormalities were mediated by desensitization of the neuronal IRs [65,68]. The stated metabolic abnormalities, as well as several of the classical histopathological lesions of AD, could be attributed in part to reduced

Table 1: Similarities between ICV-STZ model and human SAD [53].

Brain pathology	ICV-STZ rat model	Human SAD
Behavioral Cognitive deficits	Decrease memory and learning	dementia
Morphological gliosis and synaptic loss	+	+
Metabolic Glucose / energy	decrease metabolism	decrease metabolism
Neurochemical Oxidative stress Ach transmission Insulin receptor signaling	+ Decreased brain insulin resistance state	+ Decreased brain insulin resistance state
Neuropathological Tau protein Amyloid beta	+ +	+ + (Salkovic-Petrisic, 2008)

insulin levels and reduced IR function in AD. Siegfried Hoyer was among the first to suggest that reduced levels of brain insulin may precipitate a cascade resulting in disturbances in cellular glucose, Ach, cholesterol and ATP levels, impaired membrane function, accumulation of amyloidogenic derivatives, and hyperphosphorylation of tau, i.e. that SAD may represent a brain form of type 2 diabetes mellitus [58,20,57]. A comparison and correlation of various pathological changes observed in human SAD and ICV-STZ rat model are summarized in Table 1.

(A) ICV-STZ and insulin signaling alteration

Substantial evidence has been gathered in support of the presence of both insulin and IRs in the brain, and of insulin action. The main source of brain insulin is the pancreas crossing the blood–brain barrier by a saturable transport mechanism [71]. A smaller proportion of insulin is produced in the brain itself (IR signaling cascade in the brain) is similar to the one at the periphery. There are two main parallel IR intracellular pathways, the (PI3K) pathway and the Mitogen Activated Protein Kinase (MAPK) pathway [72]. When insulin binds to the subunit of IR it induces autophosphorylation of the intracellular α -subunit resulting in increased catalytic activity of the tyrosine kinase [73]. Now activated IR becomes a docking site for the IRS, which then becomes phosphorylated on tyrosine residues. IRS is now ready to bind various signaling molecules with SH2 domains; one of these molecules is (PI3K). After being activated, PI3K induces phosphorylation and subsequent activation of protein kinase B (Akt/PKB), consequently activated Akt/PKB triggers Glucose Transporter 4 (GLUT4) and also phosphorylates the next downstream enzyme Glycogen Synthase Kinase (GSK-3) which then becomes inactive Figure 1.

It has been reported that changes in the brain insulin and tau- $A\beta$ systems are observed following the bilateral applica-




Figure 1: Brain insulin receptor signaling cascade in physiological conditions.

tion of a single or multiple 1 mg/kg STZ dose into the lateral cerebral ventricles of adult 3-month-old rats [74,68,42]. Since treatment with very low to moderate doses of STZ in short term experiments causes insulin resistance [75] via a decrease in autophosphorylation [76] and decrease in total number of IRs, but with little change in phosphorylated IR- β subunit [77]. Indeed, the activity of the protein tyrosine phosphatase decreased after long-term STZ-damage [78] and induced a drastic reduction of IR dephosphorylation [79]. Regarding the enzymes downstream of the IR-PI3K pathway, experiments have shown alterations of hippocampal GSK-3 β however, observed changes were of a greater extent in the phosphorylated than in the non-phosphorylated form of GSK-3 [42]. The IR β protein was decreased in the frontoparietal cortex and hypothalamus, but the levels of phosphorylated IR β (p-IR β) were increased and tyrosine kinase activity was unchanged in these regions, whereas in the hippocampus IR β protein levels were decreased, but p-IR β levels, as well as tyrosine kinase activity were increased [113]. Downstream from the PI3K signaling pathway, hippocampal Akt/PKB remained unchanged at 4 weeks and decreased by 12 weeks post-treatment, whereas in the frontoparietal cortex Akt/PKB expression was decreased 4 weeks and increased by 12 weeks post ICV-STZ treatment. Regarding the phosphorylated GSK-3 (pGSK-3) form, levels in hippocampus were increased after 1 month, but decreased 3 months after the STZ treatment, while in the frontal cortex, pGSK-3 was found to be decreased in both observational periods, 1 and 3 months following the ICV-STZ treatment [74]. In this regard, many molecular abnormalities that characteristically occur in AD, including increased GSK-3 β activation, increased tau phosphorylation, and decreased neuronal survival, could be mediated by downstream effects of impaired insulin and IGF signaling in the CNS. This altered insulin signaling mechanisms are summarized in Figure 2.

(B) ICV-STZ and glucose and energy metabolism changes

ICV administration of STZ clearly shows heterogeneous changes in local cerebral glucose utilization after single bilateral injection in to brain ventricles in all region of cerebral cortex, in particular parietal cerebral cortex (-19%) and frontal cerebral cortex (-13%) where concentration of ADP, as well as glycogen and lactate level, were increased in the cerebral cortex and in




Figure 2: Brain insulin receptor signaling cascade in the insulin resistant brain state induced by the intracerebroventricular streptozotocin treatment. Akt/PKB: protein kinase B; IR: Insulin receptor; IGF-1R: insulin-like growth factor-1 receptor; IRS: insulin receptor substrate; tau: tau protein; tau-P: phosphorylated tau protein; PI3K: phosphatidylinositol- 3 Kinase; TK: tyrosine kinase; kinase; SAD: human sporadic Alzheimer’s disease; ICV-STZ intraverebroventricular streptozotocin [115].

Table 2: Pharmacological modulators of Calcineurin.


Pharmacological modulator	Example
Immunosuppressant	Endogenous inhibitor AKAP79, cain/cabin 1.
	Natural inhibitors Okadaic acid, microcystin LR endothal derivative, dibefurin, tautomycin, Metal- ligating phosphonates, Inhibitor protein I-1 and I-2.
	Synthetic inhibitors Cyclosporin A, tacrolimus (FK506), cypermethrin, deltamethrin, PD 144795, cantharidin, fenvalerate.
Non- immunosuppressant Analogue of FK506	GPI- 1046, GPI- 1085,V- 13667, V-13669, FK-1706, Lie-120.
Analogue of cyclosporine-A	NIM811, UNII025.

the hippocampus regions [81]. In addition, significantly diminished the activities of glycolytic enzymatic hexokinase and phosphofructokinase by 15 and 28% respectively, in parietotemporal cerebral cortex and hippocampus activity and 10-30% in brain cortex and hippocampus 3- and 6-weeks post ICV-STZ administration [81,82]. This pathologic condition, obviously sparing the metabolism in the Tricarboxylic Acid (TCA) cycle, seems to be characteristic of SAD [20] resulting in diminished concentration of the energy rich compounds ATP and creatine phosphate [51]. Interestingly, the extent of the shortage in energy production was the same in the STZ-damaged brain as in incipient SAD [58,51,83].

(C) ICV-STZ and oxidative stress

ICV-STZ treatment causes marked reduction in brain glucose/energy metabolism and shows a progressive trend towards oxidative stress [81,65,51]. Growing body of evidences indicate that STZ treatment generates Reactive Oxygen Species (ROS) that results in increased oxidative stress and additionally releases NO in brains of ICV-STZ treated rats [84,85]. Estimation of oxidative stress induced by ICV-STZ treatment commonly utilize the measurement of levels of MDA, a product of lipid peroxidation used as an indicator of free radical generation, and GSH levels, an endogenous antioxidant that scavengers free radicals and protect against oxidative and nitrosative stresses. Relevant to this oxidative-nitrosative stress has been found 1 and 8 weeks following a single ICV-STZ dose (3 mg/kg) with involvement of NO [86,87,88]. Besides oxidative stress was also found in the brain of one year old rats, 3 weeks after administration of single/low doses ICV-STZ dose (1.5 mg/kg) [89].

Significant alteration in the markers of oxidative damage thiobarbituric acid (TBARS), GSH, Protein Carbonylation (PC), Glutathione Peroxidase (GPx), Glutathione Reductase (GR) and decline in the level of ATP were observed in hypothalamus and cerebral cortex, monitored 2-3 weeks after ICV-STZ application [86,84,79,90]. A recent study demonstrated the beneficial effects of pioglitazone in the ICV- STZ induced cognitive deficits, which can be exploited for the treatment of dementia associated with diabetes and age-related neurodegenerative disorder, where oxidative stress and impaired glucose and energy metabolism are involved [79]. This is also supported by the use of naringenin [91], guggulipid [92], melatonin [93], ascorbic acid [94], mefenamic acid [95], transresveratol [96], lipoic acid [89], Centella asiatica [97], Ginko biloba [98], CoQ10 [83], ladostigil [85], melatonin and donepezil [76], curcumin [99], tocotrienol [100] and selenium [90] which prevented or reduced ICV-STZ induced behavioral, neurochemical and histological alterations via reducing free radical generation, scavenging free radicals, restoring endogenous antioxidant defenses. These data strong-

**Figure 3:** Protein Phosphatase subtypes.

ly suggest the possible therapeutic potential of antioxidant strategies in ameliorating SAD.

(D) ICV-STZ and neurotransmission deficits

The most studied neurochemical alteration in ICV-STZ injected rats is cholinergic deficit in the brain, without morphological changes in cholinergic neurons important for learning and memory [101]. ICV-STZ treated rats showed an impaired learning and memory performance, possibly as a result of cholinergic dysfunction [102]. Apart from this, Blokland and Jolles (1993, 1994), found spatial learning deficit and reduced hippocampal ChAT activity in rats one week after ICV-STZ injection [103,104]. A decrease in ChAT activity has been consistently found in the hippocampus of ICV-STZ treated rats as early as 1 week following STZ treatment and is still present 3 weeks post-injection [105]. This is followed by a significant increase in Acetylcholinesterase (AChE) activity [106, 83, 76]. A decrease in hippocampal ChAT activity was completely prevented by 2-weeks of orally administered acetyl-L-carnitine, which acts by enhancing the utilization of alternative energy sources [102,103]. Chronic administration of cholinesterase inhibitors donepezil, Ladostigil and donepezil along with melatonin reduced AChE activity in a dose-dependent manner in ICV-STZ treated rats regardless of whether treatment began 1 week prior to, in parallel or 13 days after ICV-STZ administration [106,85,76].

ICV injections of STZ affects not only the cholinergic system but also the concentration of different monoaminergic neurotransmitters (noradrenaline, dopamine, and serotonin) in the rat brain differently [107,76,108]. It has been reported that the content of whole brain monoamine (dopamine, noradrenaline, serotonin (5-hydroxy tryptamine) and 5-HT metabolite 5-hy-




Figure 4: Schematic representation of calcineurin structure.




Figure 5: Immunophilin-mediated inhibition of T-cell activation.

droxyindoleacetic acid dose-dependently increased and decreased, respectively, 1 week following ICV-STZ treatment [107].

(E) ICV-STZ and behavioral alterations

ICV-STZ treated rats consistently demonstrate deficits in learning, memory, and cognitive behavior. It is well known that ICV-STZ reduced cerebral metabolism of glucose and caused impaired cognitive performance in the delayed non-matching task [102,104], passive avoidance [51,84,83,99] and Morris water maze escape task 2 weeks after its administration [66,71,105]. These behavioral alterations were observed regardless of age in both 1–2 year [66,51] and 3-month-old rats [77,79,74,85] and also after either a single 1 or 3 mg/kg injection or multiple 1 mg/kg ICV-STZ injections. It is well documented that ICV-STZ shows dose-dependency in causing neurotoxicity with lower STZ doses induces less severe cognitive deficits [105,102,77] Most importantly, cognitive deficits are long-term and progressive, observed as early as 2 weeks after ICV-STZ administration and are maintained up to 12 weeks post treatment [51,77,74,85]. The correlation between spatial discrimination performance in the Morris water maze task and the decrease in hippocampal ChAT activity which resembles the relationship between cognitive and biochemical cholinergic changes observed in SAD has been found in ICV-STZ treated rats [105]. Chronic treatment with acetyl-L-carnitine attenuated both the STZ induced impairment in spatial bias and the decrease in hippocampal ChAT activity [102]. Interestingly, it has also been demonstrated that ICV-STZ induces development of reactive gliosis and oxidative stress 1-week post-treatment, preceded the induction of

memory deficits at 3 weeks post-treatment [85,84], where no signs of neuronal damage or any reduction in specific cholinergic markers were detected in the cortex or hippocampus [85]. Concordingly, memory deficits were reported to be prevented by chronic treatment with several types of drugs with diverse mechanisms of action [67]. Adding to this, (a) drugs generating alternative energy sources such as acetyl-L-carnitine [102], (b) cholinesterase inhibitors such as donepezil and ladostigil (possess monoamine oxidase B inhibition and neuroprotective activity) which also prevent gliosis and oxidative stress [106,85] (c) estradiol which prevents reduction in cerebral ATP [109] (d) antioxidants such as melatonin, resveratrol, and CoQ10 which prevent an increase in free radical generation [84,96,83], dose-dependently improved learning and memory thereby restoring cognitive function without affecting CNS functions.

(F) ICV-STZ and structural changes, inflammation and neurodegeneration

ICV-STZ administration has also been associated with certain brain structural changes in the brain as early as 1 week following a single dose [85] and in the brain and in both ≥ 1 year and 4-month-old rats [103,86,110,85]. In preliminary studies, Glial Fibrillary Acidic Protein (GFAP), a marker of gliosis has been found to be increased in three different protein fractions (soluble, triton X-100 soluble in cortical and subcortical structures including septum, fornix, and fimbria, striatum, and hippocampus, over a period of 3 weeks following ICV-STZ administration [65,104] suggesting that altered hippocampal function could result from direct damage to this region [86,110]. Direct histopathological evidence caused by STZ by its specific neurotoxic damage to axon and myelin in some brain region responsible for learning and spatial memory including the fornix, anterior hippocampus and periventricular areas independent of its action on glucose metabolism have been reported [103,110,67]. These pathological features are all present in the brain of SAD patients [111,112] The most prominent change, seen 3 weeks following ICV-STZ injection was a significant enlargement of golgi-apparatus, caused by expansion of trans-golgi segment of cellular protein secretory pathway in the rat cerebral cortex was found, which did not resemble Golgi atrophy found in the brain of SAD patients. Trans part of Golgi complex may influence proteolytic processing of βAPP generated in endoplasmic reticulum and in the golgi complex which accumulated in AD brain [113].

(G) ICV-STZ and Aβ and tau hyperphosphorylation

Regarding brain immunohistochemical analysis of tau pro-




Figure 6: Schematic representation of calcineurin signaling in the pathogenesis of calcium dependent disorders. Under physiological conditions, calcineurin activity is regulated by Ca²⁺/calmodulin in a reversible manner, under pathophysiological conditions calcineurin is overactivated in a reversible manner mediating pathology of several neurological and myocardial disorders [136].

tein and A expression, 3 weeks following ICV-STZ treatment both the overexpression of tau protein in the leptomenigeal vessels at all of epitopes examined in both cerebral cortex and hippocampus were demonstrated 3 weeks after ICV-STZ [114,42,80,115,116] due to insulin depletion by STZ, or caused by activation of multiple kinase by inhibition of Phosphatase (PP2A) that dephosphorylate these sites [117].

(H) ICV-STZ and phosphatase/kinase imbalance

It has been shown that GSK-3 plays a key role in numerous cell functions. It consists of two forms GSK-3 α and GSK-3 β [48]. GSK-3 α regulates the production of A β peptides, the Amyloid Precursor Protein (APP) derivatives [116]. The promotion of APP secretion from the intracellular to the extracellular space and the inhibition of its degradation by insulin-degrading enzymes are mediated by insulin and the tyrosine kinase activity of the IR [118]. Furthermore, insulin signaling via activation of PI3K regulates APP release into the extracellular space [119]. GSK-3 β isoform is involved in tau-protein phosphorylation [120]. Accumulation of hyperphosphorylated tau protein leads to the formation of NFT. The phosphorylation and dephosphorylation of the tau protein is regulated by several protein kinases, including GSK-3 β , and by several protein phosphatases, including PTP-1, -2A, -2B [47]. Prolonged exposure to insulin has been shown to induce down-regulation of GSK-3 β activity and, thus, decreased phosphorylation of tau-protein [121,122]. Within 3 days after ICV-STZ treatment after insulin depletion there is decrease in Protein Phosphatase-2A (PP2A) responsible for tau dephosphorylation, physiologically as previously implicated in pathology of AD [182] and significant increase in p38, MAPK and JNK [117]. A recent investigation focusing on the downstream PI3K signaling pathway showed drastic abnormalities of Akt/PKB level and of both phosphorylated GSK-3 α/β protein 1 and 3 month after ICV-STZ administration [77,123,115] at dose 1 mg/kg in to lateral ventricle.

Protein phosphatase superfamilies

Phosphatases remove the phosphoryl group and restore the protein to its original dephosphorylated state. The human protein phosphatase has been classified in to five groups; first group: serine/threonine phosphatase, second group: protein tyrosine phosphatase (PTP), third group: dual specificity phosphatase, fourth group: acid/alkaline phosphatase, fifth group: aspartate-based protein phosphatase with a (DXDXT/V) catalytic signature [124,125]. These families are further classified in to subclasses. Serine/threonine phosphatase into Phospho Protein Phosphatases (PPP) and Mg²⁺ and Mn²⁺ dependent protein phosphatase (PPM) characterized by their requirement for Mg²⁺ and Mn²⁺ ions for their activity [126,127]. PTP su-

perfamily in to class I PTPs (Receptor PTPs, Non receptor PTP) and is also known as DSPs (MAPKP, slingshotes, PRLSs, atypical DSP, CDC14 PTEN, myotubularins), class II PTPs (CDC 25s), class III PTPs (LMWPTP), Asp-based catalysis family include FCP/SCP family- FCP1, SCP, FCP/SCP-like class and Haloacid Dehalogenase (HAD) family [125].

Isoforms of Serine- Threonine Phosphatase


The serine/threonine protein phosphatase family members include phospho protein phosphatase (PPP) which further divided into type 1- phospho protein phosphatase 1 (PP1), and type 2- 2A (PP2A), PP2B, PP4, PP5, PP6, PP7 phosphatase [33,128,127]. Type 1 protein phosphatase dephosphorylates the β subunit of phosphorylase kinase whereas type 2 protein phosphatase dephosphorylates the α subunit of phosphorylase kinase [130]. Most importantly, PP2B also known as Calcineurin (CaN) is regulated by Ca²⁺/calmodulin. PPM comprises PP2C and pyrovalate dehydrogenase phosphotase [126,127] of which PP2C is Mg²⁺ dependent [129].

Immunophilins

Immunophilins are defined as receptors for immunosuppressive drugs including Cyclosporin A (CsA), FK506, also known as tacrolimus, and rapamycin. The CsA receptors are referred to as Cyclophilins (CYPs) and FK506- and rapamycin-binding proteins are abbreviated as FKBP. These two groups of proteins (collectively called immunophilins) share little sequence homology, but both have peptidyl prolyl cis/trans isomerase (PPIase) activity [131-133]. Small size FKBP family members contain only FK506-binding domain, while FKBP with large molecular weights possess extra domains such as tetratricopeptide repeat domains, calmodulin binding and trans membrane motifs. FKBP are a family of immunophilin proteins named according to their molecular weight (in kDa): for example, FKBP-12, -12.6, -13, -25, -38, -51, -52, -59, -60, and -65. Among these FKBP 12, 38, and 65 are enriched in the CNS [132]. Moreover, therapeutic implications of immunophilin ligands in treating neurodegenerative disorders have been accumulating. FK506 and its derivatives with no immunosuppressive activities bind to the conserved active sites of the canonical FKBP12 is the mediator of immunosuppressive action of FK506. When complexes with the tacrolimus, FKBP12 blocks nuclear import of NFAT and formation of AP-1 heterodimer, due to inhibition of calcium-dependent phosphatase CaN and JNK/p38 pathways. Suppression of these two and possibly some other signaling pathways leads to prevention of (Interleukin) IL-2 expression and T cell activation. FKBP51 and FKBP52 are natural components of glucocorticoid receptor complex and direct regulators of its activity. Upon ligand binding, FKBP51 maintaining glucocorticoid receptor in the cytoplasm is exchanged by FKBP52, which allows translocation of the complex to the nucleus. Thereby, FKBP participate in the regulation of immune response by glucocorticoids (Kochel and Strzadala, 2004). On the other hand, in the non-canonical FKBP members such as FKBP38, FK506-binding site is not conserved and shows neither PPIase activity nor affinity to FK506 [132].

Subunit and Domain Structure of Calcineurin

One of the intracellular signaling phosphatase that has recently attracted attention as a potential modulator of both memory function and cell degeneration is the Ca²⁺/calmodulin-dependent protein serine/threonine phosphatase (PP2B) also known as CaN, the most abundant phosphatase in the CNS



[134,135]. Purified calcineurin is a heterodimer consisting of catalytic subunit (calcineurin A) with mol. mass (57-59 kDa) and regulatory calcium binding subunit (calcineurin B) with mol. mass (19 kDa) (Figure 4) [136,137]. Structural and functional analysis suggests that the active site of CaN is located on the A subunit the catalytic subunit calcineurin A (521 residues) contains (residues 1-328), a CaN B binding helical domain (348-368 residues), a calmodulin binding region (390-414) & auto inhibitory loop (468 -490 residue) The gene for mammalian CaN B encodes a protein a protein of 170 amino acids containing four Ca²⁺-binding EF bands. CaN B consist of two Ca²⁺ binding domains, domain 1 (residue 1-84) and domain 2 (residue 86-169), which are arranged linearly along with its binding domain in calcineurin A, a myristoylated binding. Each domain contains two Ca²⁺-binding EF-hand motifs that are similar to those of calmodulin [136]. Mammalians have three isoforms of CaN A (α , β , γ) and two of CaN B (B1 and B2) [135-137].

Tissue Expression and Activity of Calcineurin

Previous findings reveal that the immunophilins are much more (10-100 times) abundant in the CNS highly enriched in neurons and glial cells [139] than in immune system led to the research that reveals important roles for the immunophilins in multiple areas of neural function. In the CNS, CaN is highly localized in hippocampus, striatum, substantia nigra, neocortical neurons, in layers, 3, 5, 6, and cerebellum [140]. In T lymphocytes, CaN has been found intracellularly colocalized with one of its substrates NFAT. To date, five separate genes encoding NFATs have been cloned and generally denoted NFAT1/p, NFAT2/c, NFAT3, NFAT4, and NFAT5 [141]. In addition, the presence of both immunoreactivity and enzyme activity of CaN have been reported in many other organs like lung, thymus, heart, kidney, and muscle [142,130].

Various Endogenous and Synthetic Ligands of Calcineurin:

There are two types of pharmacological inhibitor of CaN, immunosuppressant and non-immunosuppressant modulators [141,129,143]. The calcineurin modulators are enlisted in Table 2.

Biological functions of Calcineurin

(A) Physiological role of calcineurin

CaN is involved in the regulation of diverse cellular functions as gene expression, [144], cell embryonic development [145], proliferation [146], differentiation [147], migration [148], cell cycle progression [149], meiosis and mitosis [150], ion homeostasis [151], ion channel regulation [152], hormones secretion [153], neuronal transmission [154], signal transduction [155] and dopaminergic-mediated transcription in neurons, [156], embryogenesis [145], muscle differentiation [157] muscle glycogen metabolism, cyclic AMP- activated protein- kinase activity [158] and lymphocyte activation [159].

(B) Calcineurin and immunological disorders:

It is widely accepted that the most likely mechanism for the action of immunosuppressant agents involves inhibition of the activity of CaN [160,161]. By inhibiting the CaN-induced dephosphorylation of a (NFAT), FK506 and CsA prevent NFAT translocation into the nucleus where it induces interleukin-2 (IL-2) secretion, thereby preventing T-cell proliferation [132]. Members of the FKBP family play various functions within the cell. For T cell biology essential is their involvement in the regulation of cytokine genes transcription, mainly at the level of

nucleocytoplasmic transport of transcription factors. FKBP12 is the mediator of immunosuppressive action of FK506 [162] When complexed with the drug, FKBP12 blocks nuclear import of NFAT and formation of AP-1 heterodimer, due to inhibition of calcium-dependent phosphatase calcineurin. Suppression of these two and possibly some other signals pathways leads to prevention of IL-2 expression and T cell activation. FKBP51 and FKBP52 are natural components of glucocorticoid receptor complex and direct regulators of its activity. Upon ligand binding FKBP51, maintaining receptor in the cytoplasm, is exchanged by FKBP52, which allows translocation of the complex to the nucleus (Figure 5). Thereby FKBP5 take a part in the regulation of immune response by glucocorticoids [163].

C) Calcineurin and mitochondrial dysfunctions

Intracellular Ca²⁺ is a powerful secondary messenger that affects a number of calcium sensors, including calpain, a calcium-dependent cysteine protease, and CaN, a Ca²⁺/calmodulin-dependent protein phosphatase Deregulation of calpain and CaN has been implicated in the pathogenesis of several calcium dependent disorders (Figure 6) [136]. Tacrolimus, unlike CsA, does not interact with the mitochondrial permeability transmembrane pore [164] but prevents the secondary deterioration in mitochondrial respiration and rundown of adenosine triphosphate (ATP) that occurs following establishment of reperfusion [165] Tacrolimus has also been shown to attenuate the loss of mitochondrial calcium during ischaemia challenge and its accumulation following reperfusion [166]. It is of important that tacrolimus has also been reported to prevent the neurodegeneration produced by a variety of mitochondrial toxins including 3-nitropropionic acid (3-NP), a 'suicide' inhibitor of complex II [167] and the complex I inhibitor, 1-methyl-4-phenyl-1,2,3,6-tetradropyridine [168]

(D) Calcineurin and apoptotic cell death

CaN has been implicated in direct apoptotic cell death through a variety of mechanisms, namely, activation of nitric oxide synthase (NOS) interaction with the Bcl-2 family of proteins and activation of the CD95 ligand receptor pathway. It has been demonstrated that CaN, through the dephosphorylation of the proapoptotic protein BAD, may be the link between Ca²⁺ homeostasis deregulation and apoptotic neuronal death [169]. In addition, there is involvement of CaN activity in excessive stimulation of glutamate receptors leads to intracellular Ca²⁺ overload. Furthermore, CaN play a role in apoptosis in neuronal cells via the cytochrome c/caspase 3-pathway [170,171]. Calcineurin and NFAT play a role in programmed cell death of T and B lymphocytes [172] (Figure 6). Alternatively, tacrolimus and cyclosporine could act at the level of the cytosol to suppress the translocation of pro-apoptotic proteins BAX and BAD from the cytosol to the mitochondria by binding to and inhibiting the action of FKBP or calcineurin [173,174] Figure 6.

(E) Calcineurin and epileptic seizures

CaN is involved in the activation of long-term molecular cellular mechanisms leading to sustained recurrent excitatory activity, which induces late spontaneous seizures [175]. It has been reported that CaN in the brain of rats, increases after completion of electrical kindling, and two CaN inhibitors, FK506 and CsA inhibited progression of electrical kindling in rats [176] Several recent studies have demonstrated an inhibitory modulation of GABA-A receptor function by CaN [177]. CaN activity also be involved in the biochemical changes leading to picrotoxin-in-

duced epileptic seizures, because picrotoxin binding to GABA-A receptors results in a net disinhibition of cellular excitability and may lead to increased dephosphorylation. Thus, CaN inhibition might favor GABAA receptor activation antagonizing the effect of picrotoxin [178] demonstrated a significant increase in CaN activity in cortical and hippocampal homogenates during status epilepticus induced by pilocarpine, occurring through a NMDA-dependent mechanism [179]. Importantly, protective mechanism of FK506 involves the reduced formation of free radicals either directly or indirectly by NOS inhibition by CaN inhibition, thereby reducing NO formation in kindling [180].

(F) Calcineurin in ischemia

In inflammation, bacterial products and pro-inflammatory cytokines induce the expression of inducible nitric oxide synthase (iNOS) and formation of high amounts of NO and CaN inhibitors CsA, FK506 and pimecrolimus reduce iNOS expression and NO production in response to inflammatory stimuli by enhancing the decay of iNOS [181]. It has been also demonstrated that the inhibitors of CaN and PP1/PP2A could enhance nNOS phosphorylation at Ser847 site after ischemia, thus CaN inhibitors may serve as a potential and important neuroprotectant in therapy for ischemic stroke [182]. The most cited mechanism for tacrolimus- and CsA-mediated neuroprotection is by attenuation of NO-related free radical production via inhibition of NOS [183] Tacrolimus was shown to have the ability to extend the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in a clot embolization stroke model [184].

(G) Calcineurin and cardiovascular diseases

CaN also have been implicated in the pathogenesis of cardiac hypertrophy and congenital heart disease [185,186]. One prohypertrophic pathway that has received much attention involves the ubiquitously expressed Ca^{2+} /calmodulin-activated phosphatase CaN. CaN possibly plays a role in the progression of right ventricle myocardial hypertrophy in rats with chronic hypoxia. Blocking L-type Ca^{2+} channels with CsA effectively prevents the development of myocardial hypertrophy possibly by inhibiting calcium influx and suppressing CaN activity [187]. Considering the dominant role of the CaN pathway in cardiac hypertrophy and failure, CaN-inhibitory strategies may lead to the identification of novel therapeutic approaches for patients with cardiac disease [188].

(H) Calcineurin and learning and memory, Alzheimer's disease, Aging

CaN has been implicated in numerous physiological processes including learning and memory (Hernandez-Espinosa and Morton, 2006). Growing body of evidences suggested that upregulation of CaN in aged rats negatively correlates with cognitive functions [189,156] and downregulation of CaN by an autoinhibitory peptide improves memory in rodents [190]. It has been reported that CaN-mediated activation increases in rat hippocampus during aging [191]. During aging in human and rodents, overall PP1 and CaN activity increase in the brain, which might be responsible for learning and memory failures, cognitive decline and altered synaptic plasticity [134,192,154].

Abnormal tau hyperphosphorylation, one of the hallmarks of AD, might results from an imbalance between protein kinases and protein phosphatases, such as PP1, PP2A, PP2B (CaN) and PP5 [193,134,129,47]. In one of the studies in AD affected brains, PP2A, PP1, PP5 and PP2B accounted for approximately

71%, approximately 11%, approximately 10% and approximately 7%, respectively, of the total tau phosphatase activity of human brain [193]. It is also suggested that CaN-NFAT signaling pathway activation increases in intracellular calcium concentration that stimulate BACE1 expression, resulting in accelerated A β generation, in Tg2576 and its pharmacological inhibition reverses A β dependent associative learning and memory [194,195]. Apart from this, in APP/PS1 doubly transgenic mice CaN trigger inflammatory responses typical of AD [196]. More significantly, inhibition of CaN protects neuronal cells from A β -induced cell death [197] and abolishes A-induced perturbations of LTP that are promoted by A β in hippocampal slices [198].

A growing body of evidence implicates impairment in brain insulin signaling in early SAD pathology. ICV-STZ treatment causes impairment in PI3K/Akt IR signaling which further leads to decreased cerebral uptake and hypometabolism of glucose [81,80], reduced synthesis of acetyl CoA ultimately result into cholinergic deficiency [85,76] and thereby memory deficit [104,99,90]. Accumulated data indicate that CaN is negatively regulates learning and memory [134,199,200]. In addition, acute inhibition of CaN with pharmacological inhibitor FK506 restores associative learning and memory in Tg2576 APP mice [201,194]. Moreover, in a recent study, FK506 significantly improved memory performance against 3-nitropropionic acid-induced neurotoxicity [167].

Accumulating data explains the etiology of SAD that is postulated on neurochemical alterations comprise the insulin resistance, impaired glucose and mitochondrial energy metabolism [26] that lead to neuronal excitotoxicity (Shoham et al., 2007), Ca^{2+} overactivation [106], and consequently leads to kinase-phosphatase imbalance [115]. It is important to note that L-type calcium channel blockers have shown beneficial effects on learning and memory in AD patients (202) as well as in various animal models of dementia [203]. Further, reduced energy metabolism in neurons results into depolarization-induced release of glutamate causing glutamate excitotoxicity, which is blocked by L-type Ca^{2+} channel blockers. Its addition, ICV-STZ administration increased intracellular Ca^{2+} leading to consequent development of neurotoxicity which is blocked by lercanidipine, a L-type Ca^{2+} channel blocker [106,138]. Adding to this, the activities of PI3K/Akt decrease and MAPK, JNK and ERK increased following ICV-STZ administration [111]. Of particular interest, phosphatase activation is suggested to be major culprit for development of SAD and CaN a Ca^{2+} /calmodulin dependent enzyme is among the first postsynaptic phosphatase to be activated after Ca^{2+} influx [159]. Thus, CaN being a phosphatase may be involved in pathogenesis of SAD.

Oxidative stress has been implicated in the pathogenesis of AD in humans (Pratico, 2008; 204). Importantly, central STZ-induced impaired IR signaling is responsible for ATP depletion and mitochondrial disturbances that causes increased intracellular Ca^{2+} influx and generation of reactive oxygen species (ROS) leading to oxidative stress [85,138]. It has been reported that oxidative stress regulates Ca^{2+} dependent serine-threonine phosphatase, CaN [205]. In addition, mitochondrial dysfunction and oxidative stress has been observed in CaN transgenic mice indicate CaN induced oxidative stress [206]. However, the exact mechanisms of antioxidant effect of FK506 are not clear, but several possibilities can be proposed. First, FK506 possess direct radicals scavenging properties (207) and improved antioxidant defense mechanisms. It has been reported that CaN by dephosphorylation NFAT, a substrate of CaN, produces free

radicals [208] whereas FK506, inhibitor of CaN, prevented NFAT-dephosphorylation and subsequent free radical generation demonstrating the role of CaN and reduces the formation of free radicals and oxidative stress [180,209,210].

It has been reported that FK506 provide neuroprotection in haloperidol-induced orofacial dyskinesia and pentylentetrazol-induced kindling possibly by antioxidant mechanism [180,209]. Of particular relevance to this, it has been previously shown that FK506 negatively regulates Ca²⁺ channel and inhibiting Ca²⁺ dependent release of glutamate from presynaptic vesicles [211] and also inhibits the mitochondrial permeability transition opening triggered by increase in Ca²⁺ level in mitochondrial matrix [212]. In addition, FK506 is reported to protect dopaminergic and GABAergic neurons by decreasing free radical generation [180,209,213] without affecting inflammatory mechanism [214,215]. Further, ICV-STZ administration also results Ca²⁺ dependent production of NO. Further, NO as a precursor for free radicals reacts with superoxide anions to form peroxynitrite causing nitrosative stress following ICV-STZ administration [85,167]. The strongest support that CaN dephosphorylate NOS resulting in increase of NO [215]. It has been observed that FK506 by CaN inhibition and blockade of Ca²⁺ channel inhibits the free radical generation and NOS activity [217,218].

In brain, STZ causes neurodegeneration accompanied by increase in LDH activity [53]. In neurons of CNS, Ca²⁺ mobilization following glutamate stimulation of NMDA receptors is strongly implicated in cell death. The Ca²⁺ sensitivity for NOS makes Ca²⁺ dependent phosphatase CaN an obvious candidate for affecting cell death in neurons [219] and therefore, CaN may be a material factor in Ca²⁺ activated cell death in neurons [220,189]. In addition, increase in LDH level is due to the overactivation of CaN has also been reported [221,22]. It has been suggested that GSK-3 activation (GSK-3 α/β) which is activated by inhibition of inhibitor-1 (I-1) via CaN contribute towards various neuropathological changes [49]. It has been speculated that that overactivity of CaN increase the activity of GSK-3 α/β leads to memory loss [115]. Indeed, GSK-3K enhances calcineurin signaling [223]. These potential findings associate the linkage of CaN to cognitive dysfunction, impairment of cellular oxidant/antioxidant defenses, cholinergic deficits and neuronal damage following ICV-STZ administration [224].

Conclusion

In conclusion, the present findings associate the linkage of CaN to cognitive dysfunction, impairment of cellular oxidant/antioxidant defenses, cholinergic deficits and neuronal damage following ICV-STZ administration.

References

- Breitner JCS, Haneuse SJPA, Walker R, Dublin S, Crane PK, Gercy SL, et al. Risk of dementia and Alzheimer with prior exposure to NSAIDs in an elderly community based cohort. *Neurology*. 2009; 72: 1899-1905.
- Zilkens RR, Spilsbury K, Bruce DG, Semmens JB. Clinical Epidemiology and In-Patient Hospital Use in the Last Year of Life (1990-2005) of 29,884 Western Australians with Dementia. *J Alzheimers Dis*. 2009; 17: 399-407.
- Knapp M, Herrera AC, Somani A, Banerjee S. Dementia: Dementia: international comparison. Personal Social Services Research Unit, London. 2007; 14: 1-18.
- Maccioni RB, Rojo LE, Fernández JA, Kuljis RO. The role of neuroimmunomodulation in Alzheimer's disease. *Ann N Y Acad Sci*. 2009; 1153: 240-246.
- Yi J, Horky LL, Friedlich AL, Shi Y, Rogers JT, Huang X. L-Arginine and Alzheimer's Disease. *Int J Clin Exp Pathol*. 2009; 3: 211-238.
- Tong M, Dong M. Monte SMDL, Brain insulin-like growth factor and neurotrophin resistance in parkinson's disease and dementia with lewy bodies: potential role of manganese neurotoxicity. *J Alzheimers Dis*. 2009; 16: 585-599.
- Wang H, Lim PJ, Karbowski M, Monteiro M. Effects of overexpression of huntingtin proteins on mitochondrial integrity. *Hum Mol Genet*. 2009; 18: 737-752.
- Torre JCDL. Pathophysiology of neuronal energy crisis in Alzheimer's disease. *Neurodegener Dis*. 2008; 5: 126-132.
- Tanev KS, Roether M, Yang C. Alcohol dementia and thermal dysregulation: a case report and review of the literature. *Am J Alzheimers Dis Other Demen*, 2008, 23, 563-570.
- Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. *Antiviral Res*. 2009; 82: A99-109.
- Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. *Expert Rev Neurother*. 2009; 9: 591-598.
- Peng FCC. Is dementia a disease?. *Gerontology*. 2003; 49: 384-391.
- Sanchez RM, Dai W, Levada RE, Lippman JJ, Jensen FE. AMPA/kainate receptor mediated downregulation of GABAergic synaptic transmission by calcineurin after seizures in the developing rat brain. *J Neurosci*. 2005; 25: 3442-3451.
- Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. *Ann N Y Acad Sci*. 2008; 1147: 70-78.
- Reed TT, Pierce WM, Maresbery WR, Butterfield DA. Proteomic Identification of HNE bound proteins in early Alzheimer disease: Insight into the role of lipid peroxidation in the progression of AD. *Brain Res*. 2009; 1274: 66-76.
- Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer's disease. *Free Radic Biol Med*. 2009; 46: 1241-1249.
- Kamer RA, Ronald G, Craiga Ananda P, Dasanayakec Brysd M, Ann C, McKee Carrerasc I, et al. Ibuprofen reduces A β , hyperphosphorylated tau and memory deficits in Alzheimer mice. *Brain Res*. 2008; 1207: 225-236.
- Sastre M, Walter J, Gentleman MS. Interaction between APP secretase and inflammatory mediators. *J Neuroinfla*. 2008; 5: 1-11.
- Dosunmu R, Wu J, Basha MR, Zawia NH. Environmental and dietary risk factors in Alzheimer's disease. *Expert Rev Neurother*. 2007; 7: 887-900.
- Hoyer S, Riederer P. Alzheimer disease--no target for statin treatment- a mini review. *Neurochem Res*. 2007; 32: 695-706.
- Ramani A, Jens HJ, Helpert JA. Quantitative MR Imaging in Alzheimer Disease. *Radiol*. 2006; 241: 26-44.
- Michon A. The concept of mild cognitive impairment: relevance and limits in Clinical practice. *Front Neurol Neurosci*. 2009; 24: 12-29.
- Bernardi L, Geracitano S, Colao R, Puccio G, Gallo M, Anfossi M, et al. A beta PP A713T mutation in late onset Alzheimer's disease with cerebrovascular lesion. *J Alzheimer Dis*. 2009; 17: 383-389.
- Schwab C, McGeer PL. Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders. *J of Alzheimer's Dis*. 2008; 13: 359-369.

25. Xie L, Helmerhorst E, Taddel K, Plewright B, Bronswijk WV, Martins R. Alzheimer's b-amyloid peptides compete for insulin binding to the receptor. *J Neurosci*. 2002; 22: 1–5.
26. Monte SMDI, Wands JR. Alzheimer's disease is type-3 diabetes-evidence reviewed. *J of Diabetes Science and Technology*. 2008; 2: 1101-1113.
27. Hoyer S, Lannert H, Latteier E, Meisel T. Relationship between cerebral energy metabolism in parietotemporal cortex and hippocampus and mental activity during aging in rats. *Neural Transm*. 2004a; 111: 575-589.
28. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer's disease. *J Clin Invest*. 2005; 115: 1121–1129.
29. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. *Neurobiol Aging*. 2006; 27: 252-261.
30. Gella A, Durany N. Oxidative stress in Alzheimer disease. *Cell Adh Migr*. 2009; 3: 208-213.
31. Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R, et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. *Ageing Res Rev*. 2009; 8: 285-305.
32. Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer disease. *J of Alzheimer Dis*. 2009; 16: 225-233.
33. Wang BO, Zhou S, Yang Z, Xie YC, Wang J, Zhang P, et al. Genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A and Saitohin Q7R polymorphisms with Alzheimer's disease. *J Neurol Sci*. 2008; 270: 148-151.
34. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, et al. Beta-Amyloid impairs axonal BDNF retrograde trafficking. *Neurobiol Aging*. 2009; 13: 543-545.
35. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. *J Alzheimers Dis*. 2008; 13: 241-253.
36. Koh SH, Noh MY, Kim SH. Amyloid beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. *Brain Res*. 2008; 1188: 254-262.
37. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces Aβ hyperphosphorylated tau and memory deficits in Alzheimer mice. *Brain Res*. 2008; 1207: 225-236.
38. Placanica L, Zhu L, Li YM. Gender-and Age-Dependent c-Secretase activity in mouse brain and its implication in Sporadic Alzheimer Disease. *Plos One*. 2009; 4: e5088.
39. Cizza G, Calogero AE, Brady LS, Bagdy G, Bergamini E, Blackman MR, et al. Male Fischer 344-N rats show a progressive central impairment of the hypothalamic-pituitary-adrenal axis with advancing age. *Endocrinology*. 1994; 134: 1611–1620.
40. Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE, et al. Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. *J R Neurobiol Dis*. 2006; 21: 256-275.
41. Droge W, Kinscherf R. Aberrant insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging. *Antioxid Redox Signal*. 2008; 10: 661–678.
42. Coll NL, Rivera EJ, Soscia SJ, Doiron K, Wands JR, Monte SMDL. Intracerebral streptozotocin model of type 3 diabetes relevance to Sporadic Alzheimer's disease. *J Alzheimer dis*. 2006; 9: 13-33.
43. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease- is this type 3 diabetes?. *J Alzheimer Dis*. 2005; 7: 63-80.
44. Dong W, Albers JJ, Vuletic S. Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. *J Neurosci Res*. 2009; 87: 3176-85.
45. Sun Q, Gamblin TC. Pseudo-hyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. *Biochem*, 2009; 48: 6002-6011.
46. Giese KP. GSK-3a key player in neurodegeneration and memory. *IUBMB Life*. 2009; 61: 516-521.
47. Liang Z, Liu F, Iqbal K, Iqbal IG, Gong CX. Dysregulation of Tau Phosphorylation in Mouse Brain during Excitotoxic Damage. *J Alzheimer Dis*. 2009; 17: 531-539.
48. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. *J Neurochem*. 2008; 104: 1433-1439.
49. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, et al. The role of GSK-3 in synaptic plasticity. *BJP*. 2008; 153: S428–S437.
50. Maurer K, Hoyer S, Alois. Alzheimer revisited: differences in origin of the disease carrying his name *J Neural Transm*. 2006; 113: 1645–1658.
51. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. *Behav Neurosci*. 1998; 112: 1199–1208.
52. Gong CX, Liu F, Iqbal IG, Iqbal K. Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer's disease: A Therapeutic Target. *J of Biomed and Biotech*. 2006; 31825: 1–11.
53. Hoyer S, Lannert H. Long-term abnormalities in brain glucose-energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. *J Neural Transm*. 2007; 72: 195–202.
54. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. *Med Hypotheses*. 2004; 63: 8-20.
55. Dorner AJ, Wasley LC, Kaufman RJ. Protein dissociation from GRP78 and secretion are blocked by depletion of cellular ATP levels. *Proc Natl Acad Sci USA*. 1990; 87: 7429– 7432.
56. Sun FF, Fleming WE, Taylor BM. Degradation of membrane phospholipids in the cultured human astroglial cell line UC-11MG during ATP depletion. *Biochem Pharmacol*. 1993; 45: 1149–1155.
57. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. *Brain Res Review*. 2007; 56: 384-402.
58. Hoyer S, The brain insulin signal transduction system and sporadic (type ii) Alzheimer disease: an update. *J of neural transm*, 2002, 109, 341-360.
59. Woodhouse A, Shepherd CE, Sokolova A, Carroll VL, King AE, Halliday GM, et al. *Acta Neuropathol*. 2009; 117: 19-29.
60. Ding H, Johnson GVW. The last tangle of tau. *J Alzheimers Dis*. 2008; 14: 441-447.
61. Bruden RK, Trojanowski JQ, Lee VMY. Evidence that nonfibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. *J of Alzheimer dis*. 2008; 14: 393-399.

62. Takashima A. Amyloid-beta, Tau, and Dementia. *J Alzheimers Dis.* 2009.
63. Blennow K, Leon MJD, Zetterberg H. Alzheimer's disease. *Lancet.* 2006; 368: 387-403.
64. Bamburg JR, Bloom GS. Cytoskeletal pathologies of Alzheimer disease. *Cell Motil Cytoskeleton.* 2009.
65. Duelli R, Schrock H, Kuschinsky W, Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. *Int J Dev Neurosci.* 1994; 12: 737-743.
66. Mayer G, Nitsch R, Hoyer S. Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats. *Brain Res.* 1990; 532: 95-100.
67. Weinstock M, Shoham S. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. *J Neural Transm.* 2004; 11: 347-366.
68. Monte SMDL, Tong M, Coll NLC, Plater JR M, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. *J Alzheimer Dis.* 2006; 10: 89-109.
69. Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acid subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. *J of Neural Transm.* 1989; 75: 227-232.
70. Blokland A, Jolles J. Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin. *Pharmacol Biochem Behav.* 1993; 44: 491-494.
71. Banks WA. The source of cerebral insulin. *Eur J Pharmacol.* 2004; 490: 5-12.
72. Johanson GV, Bailey CD. The p38 and MAPK signaling pathway in Alzheimer disease. *Exp Neurol.* 2003; 183: 262-268.
73. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. *Eur J Pharmacol.* 2004b; 490: 115-125.
74. Salkovic-Petrisic MF, Osmanovic JT, Schmidt M, Hoyer S, Riederer P. Streptozotocin-intracerebroventricularly treated rats: Behavioral, neurochemical and structural resembling to the human sporadic type of Alzheimer's disease. *Alzheimer Apopt and Dement.* 2006; 2: S238-S238.
75. Blondel O, Portha B. Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. *Diabetes Metab.* 1989; 15: 382-387.
76. Agrawal R, Tyagi E, Shukla R, Nath C. A Study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. *Neuropharmacol.* 2009; 56: 779-787.
77. Grünblatt E, Koutsilieris E, Hoyer S, Riederer P. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. *J Alzheimers Dis.* 2006; 9: 261-271.
78. Mayevich J, Backer JM, Khan CR. Hepatic phosphotyrosine phosphatase activity and its alteration in diabetic rats. *J Clin Invest.* 1989; 84: 976-983.
79. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. *Life Sci.* 2006; 79: 2209-2216.
80. Grünblatt E, Petrisic MS, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. *J Neurochem.* 2007; 101: 757-770.
81. Nitsch R, Hoyer S. Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. *Neurosci Lett.* 1991; 128: 199-202.
82. Plaschke K, Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. *Int J Dev Neurosci.* 1993; 11: 477-483.
83. Ishrat T, Khan MB, Hoda MdN, Yousuf S, Ahmad M, Ansari MA, et al. Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. *Behav Brain Res.* 2006; 171: 9-16.
84. Sharma M, Gupta YK. Intracerebroventricular injection of streptozotocin in rats produce both oxidative stress in the brain and cognitive impairment. *Life Sci.* 2001a; 68: 1021-1029.
85. Shoham S, Bejar C, Kovalev E, Schorer-Apelbaum D, Weinstock M. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. *Neuropharmacol.* 2007; 52: 836-843.
86. Prickaerts J, De Vente J, Honig W, Steinbusch H, Ittersum MMV, Blokland A, et al. Nitric oxide synthase does not mediate neurotoxicity after an i.c.v. injection of streptozotocin in the rat. *J Neural Transm.* 2000; 107: 745-766.
87. Tahirovic I, Sofic E, Sapcanin A, Gavrankapetanovic I, Bach-Rojecky L, Salkovic-Petrisic M, et al. Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus. *J Neural Transm.* 2007; 32: 235-240.
88. Tong M, Neusner A, Longato L, Lawton M, Wands JR, de la Monte SM. Nitrosamine Exposure Causes Insulin Resistance Diseases: Relevance to Type 2 Diabetes Mellitus, Non-Alcoholic Steatohepatitis, and Alzheimer's Disease. *J Alzheimers Dis.* 2009; 17: 827-44.
89. Sharma M, Gupta YK. Effect of alpha lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in rats. *E Neuro Pharm.* 2003; 13: 241-247.
90. Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S, et al. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's disease. *Brain Res.* 2009b; 20: 1-10.
91. Balchnejadmojarad T, Roghani M. Effect of Naringenin of intracerebroventricular streptozotocin-induced cognitive deficits in rats: A behavioral analysis. *Pharmacology.* 2006; 73: 193-197.
92. Saxena G, Singh PS, Pal R, Singh S, Pratap R, Nath C. Gugulipid, an extract of *Commiphora whighitti* with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. *Pharmacol Biochem and Behav.* 2007b; 86: 797-805.
93. Sharma M, Gupta YK. Effect of chronic treatment of melatonin on learning, memory and oxidative deficiencies induced by intracerebroventricular streptozotocin in rats. *Pharmacol Biochem Behav.* 2001b; 70: 325-331.
94. Weerateerangkull P, Praputpittaya C, Banjerdponchai R, Effects of Ascorbic acid on streptozotocin- induced oxidative stress and memory impairment in rats. *J Physiol Sci.* 2008; 20: 54-61.
95. Mojard TB, Mehrdad R, Iranian SH. Mefenamic Acid attenuates Intracerebroventricular Streptozotocin-Induced Cognitive Deficits in the Rat: A Behavioral Analysis. *J Pharmacol and Ther.* 2007; 6: 45-49.
96. Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. *Life Sci.* 2002; 71: 2489-2498.

97. Kumar V, Gupta YK. Effect of *Centella asiatica* on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. *Clin Exp Pharmacol Physiol*. 2003; 30: 336–342.
98. Hoyer S, Lannert H, Noldner M, Chatterjee SS. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). *J Neural Transm*. 1999; 106: 1171–1188.
99. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). *Eur Neuropsychopharmacol*. 2009a; 21: 1–12.
100. Tiwari V, Kuhad A, Bishnoi M, Chopra K. Chronic treatment with tocotrienol, an isoform of Vit E, prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative nitrosative stress. *Pharmacol Biochem Behav*. 2009; 93: 183–189.
101. Spencer DG, Lal H. Effects of anticholinergic drugs on learning and memory. *Drug Dev Res*. 1983; 3: 489–502.
102. Prickaerts J, Blokland A, Honig W, Meng F, Jolles J. Spatial discrimination learning and choline acetyl transferase activity in streptozotocin-treated rats: effects of chronic treatment with acetyl-L-carnitine. *Brain Res*. 1995; 674: 142–146.
103. Terwel D, Prickaerts J, Meng F, Jolles J. Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. *Eur J Pharmacol*. 1995; 287: 65–71.
104. Prickaerts J, Fahrig T, Blokland A. Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. *Behav Brain Res*. 1999; 102: 73–88.
105. Blokland A, Jolles J. Behavioral and biochemical effects of an ICV injection of streptozotocin in old Lewis rats. *Pharmacol Biochem Behav*. 1994; 47: 833–837.
106. Sonkusare S, Srinivasan K, Kaul C, Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. *Life Sci*. 2005; 77: 1–14.
107. Lackovick Z, Salkovic M. Streptozotocin and alloxan produce alterations in rat brain monoamines independently of pancreatic beta cells destruction. *Life Sci*. 1990; 46: 49–54.
108. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. *Methods Enzymol*. 1990; 186: 464–478.
109. Lannert H, Wirtz P, Schuhmann V, Galmbacher R. Effects of Estradiol (-17beta) on learning, memory and cerebral energy metabolism in male rats after intracerebroventricular administration of streptozotocin. *J Neural Transm*. 1998; 105: 1045–1063.
110. Shoham S, Bejar C, Kovalev E, Weinstock M. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. *Exp Neurol*. 2003; 184: 1043–1052.
111. De la Monte SM, Tong M. Mechanisms of Nitrosamine-Mediated Neurodegeneration: Potential Relevance to Sporadic Alzheimer's disease. *J Alzheimers Dis*. 2009; 17: 827–844.
112. Grünblatt E. Commonalities in the genetics of Alzheimer's disease and Parkinson's disease. *Expert Rev Neurother*. 2008; 8: 1865–1877.
113. Grieb P, Kryczka T, Fiedorowicz M, Frontczak-Baniewicz M, Waliski M. Expansion of the Golgi apparatus in rat cerebral cortex following intracerebroventricular injections of streptozotocin. *Acta Neurobiol Exp (Wars)*. 2004; 64: 481–489.
114. Chu WZ, Qian CY. Expressions of Abeta1-40, Abeta1-42, tau202, tau396 and tau404 after intracerebroventricular injection of streptozotocin in rats. 2005; 25: 168–170.
115. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. *J Neural Transm*. 2007; 72: 217–233.
116. Martin L, Magnaudeixa A, Esclaire F, Yardina C, Terroa F. Inhibition of glycogen synthase kinase-3 β downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. *Brain research*. 2009; 12: 266–275.
117. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. *Diabetes*. 2006; 55: 3320–3325.
118. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduce intraneural beta-amyloid and requires mitogen-activated protein kinase signalling. *J Neurosci*. 2001; 21: 2561–2570.
119. Solano DC, Sironi M, Bonfini C, Solarte SB, Govani S, Racchi M. Insulin regulates soluble amyloid precursor protein release via Phosphatidylinositol 3-kinase dependent pathway. *FASEB J*. 2000; 14: 1015–1022.
120. Hernández F, Barreda EG, Fustermatanzo A, Olivergoni P, Avila JLL. The role of GSK3 in Alzheimer Disease. *J Brain Res Bull*. 2009; 80: 248–50.
121. Cross DAE, Watt PW, Shaw M, Von der Kaay J, Downes CP, Holder JC, et al. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin insensitive pathways in skeletal muscle and adipose tissue. *FEBS Lett*. 1997; 406: 211–215.
122. Yeh HL, Tsai SJ. Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease. *Med Hypotheses*. 2008; 71: 948–951.
123. Li X, Lu F, Tian Q, Yang Y, Wang Q, Wang JZ. Activation of glycogen synthase kinase-3 induces Alzheimer like tau hyperphosphorylation in rat hippocampus slices in culture. *J Neural Transm*. 2006; 113: 93–102.
124. Tonks NK. Protein tyrosine phosphatase: from genes to function, to disease. *Nature Rev Mol Cell Bio*. 2006; 7: 833–846.
125. Moorhead GBG, Mulcahy-Trinkle L, Lemee-Ulke A. Emerging role of nuclear protein phosphatase. *Nature*. 2007; 8: 234–244.
126. Kitajima TS, Sakuno T, Ishiguro K, Iemura S, Natsume T, Kawashima SA, et al. Shugosin collaborates with protein phosphatase 2A to protect cohesion. *Nature*. 2006; 441: 46–52.
127. Klumpp S, Thissen MC, Krieglstein J. Protein phosphatase types 2Calpha and 2Cbeta in apoptosis. *Biochem Society transact*. 2006; 34: 1370–1375.
128. Shenolikar S, Nairn AC. Protein phosphatases: recent progress. *Adv Second Messenger Phosphoprotein Res*. 1991; 23: 1–121.
129. Wang ZJ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. *Eur J of Neurosci*. 2007; 25: 59–68.
130. Rusnak F, Nertz P. Calcineurin: Form and Function. *Physiol Rev*. 2000; 80: 1483 – 1521.
131. Adams B, Musiyenko A, Kumar R, Barik S, Kumar P. A novel class of dual family immunophilins. *J Biol Chem*. 2005; 280: 24308–24314.
132. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS. FKBP family proteins: Immunophilins with versatile biological functions. *Neurosignals*. 2008; 16: 318–325.

133. Somarelli JA, Lee SY, Skolnick J, Herrera RJ. Structure-based classification of 45 FK506-binding proteins. *Proteins*. 2008; 72: 197–208.
134. Mansuy MI, Shenolikar S. Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory. *Trends in Neurosci*. 2006; 29: 679-686.
135. Mathieu F, Miot S, Etain B, Khoury MA, Chevalier F, Bellivier F, et al. Association between the PPP3CC gene, coding for the calcineurin gamma catalytic subunit, and bipolar disorder. *Behav Brain Funct*. 2008; 4: 2.
136. Wu YH, Tomizawaa K, Matsua H. Calcain-calcineurin signaling in the Pathogenesis of Calcium-dependent Disorder. *Acta Med Okayama*. 2007; 61: 123-137.
137. Shen X, Li H, Ou Y, Tao W, Dong A, Kong J, et al. The secondary structure of calcineurin regulatory region and conformational change induced by calcium/calmodulin binding. *J Biol Chem*. 2008; 283: 11407-11413.
138. Muller D, Nitsch RM, Wurtman RJ, Hoyer S. Streptozotocin increases free fatty acids and decreases phospholipids in rat brain. *J Neural Transm*. 1998; 105: 1271–1281.
139. Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. *Curr Top Med Chem*. 2003; 3: 1376-1382.
140. Liu D, McIlvain HB, Fennell M, Dunlop J, Wood A, Zaleska MM, et al. Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells. *J Neurosci Methods*. 2007; 163: 310-320.
141. Morioka M, Hamada IJ, Ushio Y, Miyamoto Y. Potential role of calcineurin for brain ischemia and traumatic injury. *Progress in Neurobiology*. 1999; 58: 1-30.
142. Shibasaki FU, Uchino HH. Calcineurin as a multifunctional regulator. *J Biochem*. 2002; 131: 1-15.
143. Gold BG, Armistead MD, Wang SM. Non-Fk506-binding protein-12 Neuroimmunophilin Ligands increase neurite elongation and accelerate nerve regeneration. *J Neurosci Res*. 2005; 80: 56-65.
144. Oh-hora M, Rao A. Calcium signaling in lymphocytes. *Curr Opin Immunol*. 2008; 20: 250-258.
145. Muller MR, Sasaki Y, Stevanovic I, Lamperti ED, Ghosh S, Sharma S, et al. Requirement for balanced Ca/NFAT signaling in hematopoietic and embryonic development. *Proc Natl Acad Sci USA*. 2009; 106: 7034-7039.
146. Pang X, Sun NL. Calcineurin-NFAT signaling is involved in phenylephrine-Induced vascular smooth muscle cell proliferation. *Acta Pharmacol Sin*. 2009; 30: 537-544.
147. Kao SC, Wu H, Xie J, Chang CP, Ranish JA, Graef IA, et al. Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation. *Science*. 2009; 323: 651-654.
148. Sordi V, Bianchi G, Buracchi C, Mercalli A, Marchesi F, Amico G, et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. *Transplant*. 2006; 82: 826-834.
149. Alev C, Wu Y, Nakazawa F, Asahara T, Sheng G. NFATc 2 ser 170 phosphorylation marks mitosis in development and ES cells. *Cell Cycle*. 2009; 8: 1803-1805.
150. Mochida S, Hunt T. Calcineurin is required to release *Xenopus* egg extracts from meiotic M phase. *Nature*. 2008; 449: 336-340.
151. Kanatous SB, Mammen PP, Rosenberg PB, Martin CM, White MD, Dimaio JM, et al. Hypoxia reprograms calcium signaling and regulates myoglobin expression. *J Am J Physiol Cell Physiol*. 2009; 296: C393-C402.
152. Tyagi MG, Nandhakumar F. Newer insights into renal regulation of water homeostasis. *J Indian J Exp Biol*. 2008; 46: 89-93.
153. Williams JA. Receptor-mediated signal transduction pathways and the regulation of pancreatic acinar cell function. *Curr Opin Gastroenterol*. 2008; 24: 573-579.
154. Christie-Fougere MM, Darby-King A, Harley CW, McLean JH. Calcineurin inhibition eliminates the normal inverted U curve, enhances acquisition and prolongs memory in a mammalian 3'-5'-cyclic AMP-dependent learning paradigm. *Neuroscience*. 2009; 158: 1277-1283.
155. Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kranner SD, et al. Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. *J Biol Chem*. 2008; 283: 21953-21964.
156. Hernández-Espinosa D, Morton AJ. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. *Brain Res Bull*. 2006; 69: 669-679.
157. Nilsson LM, Sun ZW, Nilsson J, Nordstrom I, Chen YW, Molkentin JD, et al. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. *Am J Physiol Cell Physiol*. 2007; 292: C1167-1178.
158. Orié NN, Thomas AM, Perrino BA, Tinker A, Clapp L. Protein kinase A pathway. *Br J Pharmacol*. 2009; 554-564.
159. Liu JO. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. *Immunol Rev*. 2009; 228: 184-198.
160. Kaminuma O. Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases. *Inflamm Allergy Drug Targets*. 2008; 7: 735-740.
161. Liu Z, Yuan X, Luo Y, He Y, Jiang Y, Chen ZK, et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood. *Cytokine*. 2009; 45: 141-147.
162. Van Rossum HH, Romijn FP, Smit NP, de Fijter JW, Van Pelt J. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein. *Biochem Pharmacol*. 2009; 77: 1206-1212.
163. Kochel I, Strzadala L. FK506-binding proteins in the regulation of transcription factors activity in T cells. *Postepy Hig Med Dosw*. 2004; 58: 118-127.
164. Vindis C, Elbaz M, Escargueil-Blanc I, Augé N, Heniquez A, Thiers JC, et al. Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-I induced apoptosis. *Arterioscler Thromb Vasc Biol*. 2005; 25: 639-645.
165. Nakai A, Kuroda S, Siesjo BK. Protective effect of FK506 on secondary mitochondrial dysfunction due to transient focal cerebral ischemia in the rat. *J Cereb Blood Flow Meta*. 1997; 17: S665.
166. Dhar DK, Takemoto Y, Nagasue N. FK506 maintains cellular calcium homeostasis in ischemia. Reperfusion injury of the canine liver. *J Surg Res*. 1996; 60: 142-146.
167. Kumar P, Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. *Neurosci Res*. 2009; 63: 302-314.

168. Kitamura Y, Itano Y, Kubo T. Suppressive effect of FK506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. *J Neuroimmunol.* 1994; 50: 221-224.
169. Agostinho P, Lopes JP, Velez Z, Oliveira CR. Over activation of calcineurin induced by amyloid-beta and prion proteins. *Neurochem Int.* 2008; 52: 1226-1233.
170. Klettner A, Herdegen T. The immunophilin-ligands FK506 and V-10, 367 mediate neuroprotection by the heat shock response. *Br J Pharmacol.* 2003b; 138: 1004-1012.
171. Li JY, Furuichi Y, Matsuoka N, Mutoh S, Yanagihara T. Tacrolimus (FK506) attenuates biphasic cytochrome c release and bad phosphorylation following transient cerebral ischemia in mice. *Neurosci.* 2006; 142: 789-797.
172. Luoma JI, Zirpel L. Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. *J Neurosci.* 2008; 28: 3159-3169.
173. Gabryel B, Chalimoniuk M, Stolecka A, Waniek K, Langfort J, Malecki A. Inhibition of arachidonic acid release by cytosolic phospholipase a2 is involved in the antiapoptotic effect of fk506 and cyclosporin a on astrocytes exposed to simulated ischemia in vitro. *J Pharmacol Sci.* 2006; 102: 77-87.
174. Shioda N, Han F, Moriguchi S, Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. *J Neurochem.* 2007; 102: 1506-1517.
175. Wang A, Chi Z, Wang S, Wang S, Sun Q. Calcineurin-mediated GABA (A) receptor dephosphorylation in rats after kainic acid-induced status epilepticus seizure. *J Mol Cell Cardiol.* 2009; 18: 519-23.
176. Moia L, Matsui H, de Barrose GAM, Tomizawa K, Miyamoto K, Kuwata Y, et al. Immunosuppressant and calcineurin inhibitor cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdala kindled rat. *Brain Res.* 1994; 648: 337-341.
177. Sanchez RM, Dai W, Levada RE, Lippman JJ, Jensen FE. AMPA/kainate receptor mediated down regulation of GABAergic synaptic transmission by calcineurin after seizures in the developing rat brain. *J Neurosci.* 2005; 25: 3442-3451.
178. Vázquez-López A, Sierra-Paredes G, Sierra-Marcuño G. Anticonvulsant effect of the calcineurin inhibitor ascromycin on seizures induced by picrotoxin microperfusion in the rat hippocampus. *Pharmacol Biochem Behav.* 2006; 84: 511-516.
179. Setkowicz Z, Ciarach M. Neuroprotectants FK-506 and cyclosporin A ameliorate the course of pilocarpine-induced seizures. *Epilepsy Res.* 2007; 73: 151-155.
180. Singh A, Kumar G, Naidu SP, Kulkarni KS. Protective effect of FK-506 (Tacrolimus) in pentylenetetrazol- induced kindling in mice. *Pharmacol Biochem and Behav.* 2003a; 75: 853-860.
181. Hamalainen M, Korhonen R, Moilanen E. Calcineurin inhibitors down-regulate Inos expression by destabilizing mRNA. *Int Immunopharmacol.* 2009; 9: 159-167.
182. Zhou XW, Gustafsson JA, Tanila H, Bjorkdahl C, Liu R, Winblad B, et al. Hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. *Neurobiol Dis.* 2008; 31: 386-394.
183. Huser N, Doll D, Altomonte J, Werner M, Kriner M, Preissel A, et al. Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat. *Arch Pharm Res.* 2009; 32: 215-220.
184. Maeda M, Furuichi Y, Noto T, Matsuoka N, Mutoh S, Yoneda Y. Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model. *Brain Res.* 2009; 1254: 99-108.
185. Groetzner J, Reichart B, Roemer U, Reichel S, Kozlik-Feldmann R, Tiete A, et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. *Ann Thorac Surg.* 2005; 79: 53-60.
186. Iyer A, Brown L. Is mycophenolate more than just an immunosuppressant? An overview. *J Biochem Biophys.* 2009; 46: 25-30.
187. Colella M, Grisan F, Robert V, Turner JD, Thomas AP, Pozzan T. Ca²⁺ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca²⁺ signal integrators. *Proc Natl Acad Sci USA.* 2008; 105: 2859-2864.
188. Wilkins J, Benjamin YSD, Orlando F, Stephanie A, Xu PJ, David M. Calcineurin/NFAT coupling participates in pathological, but not physiological cardiac hypertrophy. *Circ Res.* 2004; 94: 110-118.
189. Norris CM, Inga K, Eric M, Blalock K, Chu C. Calcineurin Triggers Reactive/Inflammatory Processes in Astrocytes and Is Upregulated in Aging and Alzheimer's Models. *J Neurosci.* 2005; 25: 4649-4658.
190. Malleret G, Haditsch U, Genoux D, Jones MW, Bliss TVP, Vanhoose AM, et al. Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. *Cell.* 2001; 104: 675-686.
191. Eto R, Abe M, Hayakawa N, Kato H, Araki T. Age-related changes of calcineurin and Akt1/protein kinase Balpha (Akt1/PKBalpha) immunoreactivity in the mouse hippocampal CA1 sector: an immunohistochemical study. *Metab Brain Dis.* 2008; 23: 399-409.
192. Morita M, Imai H, Liu Y, Xu X, Sadamatsu M, Nakagami R, et al. FK506-protective effects against trimethyltin neurotoxicity in rats: hippocampal expression analyses reveal the involvement of periaxonal osteopontin. *Neuroscience.* 2008; 153: 1135-1145.
193. Liu F, Grundke-Iqbal I, Iqbal K, Cheng-Xin G. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. *Eur J Neurosci.* 2005; 22: 1942-1950.
194. Tagliatela G, Hogan D, Zhang WR, Dineley KT. Intermediate and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. *Behav Brain Res.* 2009; 200: 95-99.
195. Reese LC, Zhang W, Dineley KT, Kaye R, Tagliatela G. Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. *Aging Cell.* 2008; 7: 824-835.
196. Norris CM, Blalock EM, Chen KC, Porter NM, Thibault O, Kraner SD, et al. Hippocampal 'zipper' slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca (2+) channels with aging. *Neurobiol.* 2008; 31: 328-38.
197. Kazmierczak A, Strosznajder JB, Adamczyk A. Alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. *Neurochem Int.* 2008; 53: 263-269.
198. Lam BY, Zhang W, Enticknap N, Haggis E, Cader MZ, Chawla S. Inverse regulation of plasticity-related immediate early genes by calcineurin in hippocampal neurons. *J Biol Chem.* 2009; 284: 12562-12571.
199. Havekes R, Nijholt IM, Luiten PGM, Vander Zee EA. Differential involvement of hippocampal calcineurin during learning and reversal learning in a Y-maze task. *Learn Mem.* 2006; 13: 753-759.
200. Baumgartel K, Genoux D, Welzl H, Tweedie-Cullen RY, Koshibu K, Livingstone-Zatchej M, et al. Control of the establishment of aversive memory by calcineurin and Zif268. *Nat Neurosci.* 2008; 11: 572-578.

201. Dineley KT, Hogan D, Zhang WR, Tagliatalata G. Acute inhibition of Calcineurin in restores associative learning and memory in Tg2576 APP transgenic mice. *Neurobiol Learn Mem.* 2007; 88: 217-224.
202. Fritze J, Walden J. Clinical findings with nimodipine in dementia: test of the calcium hypothesis. *J of Neural Transm.* 1995; 46: 439-453.
203. Quartermain D, Garcia deSoria V. The effects of calcium channel antagonists on short-and long-term retention in mice using spontaneous alternation behavior. *Neurobiol of Learn Mem.* 2001; 76: 117-124.
204. Manik C, Ghosh-Xuton W, Li S, Klee C. Regulation of calcineurin by oxidative stress. *Methods in enzymol.* 2003; 366: 289-304.
205. Sayen MR, Gustafsson AB, Sussman MA, Molkentin JD, Gottlieb AR. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. *An J Physiol.cell Physiol Brain Res.* 2008; 284: C562-C570.
206. Maziere C, Morlière P, Massy Z, Kamel S, Louandre C, Conte MA, et al. Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. *Free Radic Biol Med.* 2005; 38: 472-480.
207. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. *Nature.* 1994; 371: 336-339.
208. Singh A, Kumar G, Naidu PS, Kulkarni SK. Protective effect of FK-506 (Tacrolimus) in pentylenetetrazol- induced kindling in mice. *Pharmacol Biochem and Behav.* 2003a; 75: 853-860.
209. Singh A, Kumar G, Naidu PS, Kulkarni SK. Possible antioxidant and neuroprotective mechanisms of FK-506 in attenuating haloperidol-induced orofacial dyskinesia. *Eur J of Pharmacol.* 2003b; 477: 87-94.
210. Kaymaz M, Emmez H, Bukan N, Dursun A, Kurt G, Paşaoglu H, et al. Effectiveness of FK506 on lipid peroxidation in the spinal cord following experimental traumatic injury. *Spinal Cord.* 2005; 43: 22-26.
211. Victor RG, Thomas GD, Marbant E, Rourket OB. Presynaptic modulation of cortical synaptic activity by calcineurin. *Proc Natl Acad Sci USA Neurobiology.* 1995; 92: 6269-6273.
212. Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses. *J Cell Mol Med.* 2004; 8: 45-58.
213. Manáková S, Singh A, Kaariainen T, Taari H, Kulkarni SK, Manisto PT. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. *Brain Res.* 2005; 1038: 83-91.
214. Gerard M, Debyser Z, Desender L, Kahle PJ, Baert J, Baekelandt V, et al. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. *FASEB J.* 2006; 12: 1-21.
215. Wright AK, Miller C, Williams M, Arbuthnott G. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression. *Brain Res.* 2008; 1216: 78- 86.
216. Knirsch U, Sturm S, Reuter A, Bachus R, Gosztanyi G, Voelkel H, et al. Calcineurin A and calbindin immunoreactivity in the spinal cord of G93A superoxide dismutase transgenic mice. *Brain Res.* 2001; 889: 234-238.
217. Phillis JW, Diaz FG, O'Regan MH, Pilitsis JG. Effects of immunosuppressants, calcineurin inhibition, and blockade of endoplasmic reticulum calcium channels on free fatty acid efflux from the ischemic/reperfused rat cerebral cortex. *Brain Res.* 2002; 957: 12-24.
218. Sasaki T, Hamada J, Shibata M, Gotoh J, Araki N, Fukuuchi Y. FK506 abrogates delayed neuronal death via suppression of nitric oxide production in rats. *Brain Res.* 2004; 1009: 34-39.
219. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Urh GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. *Proc Natl Acad Sci USA Neurobiol.* 1993; 90: 9808-9812.
220. Shibasaki F, Mckeeon F. Calcineurin functions in Ca²⁺-activated cell death in mammalian cells. *The J Cell Biol.* 1995; 131: 735-743.
221. Davis PK, Dudek SM, Johnson GVW. Select alteration in protein kinases and phosphatase during apoptosis of differentiated PC12 cells. *J Neurochem.* 1997; 68: 2338-2347.
222. Wei Q, Holzer M, Brueckner MK, Liu Y, Arendt T. Dephosphorylation of Tau Protein by Calcineurin Triturated into Neural Living Cells. *Cell and Mol Neurobiol.* 2008; 22: 13-24.
223. Hilioti Z, Gallagher DA, Low-Nam ST, Ramaswamy P, Gajer P, Kingsbury TJ, et al. GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs. *Genes and development.* 2004; 18: 35-47.
224. Salkovic-Petrisic M. Amyloid cascade hypothesis: is it true for sporadic Alzheimer's disease. *Periodicum Biologum.* 2008; 110: 17-25.